Home · Peptide Library · Zepbound
Zepbound
Zepbound is the FDA-approved weight-loss drug from Eli Lilly. It's a higher-dose form of tirzepatide, the same active ingredient in Mounjaro, approved specifically for chronic weight management.
- Active ingredient
- Tirzepatide
- Prescribed dose
- 2.5–15 mg weekly (titrated)
- Manufacturer
- Eli Lilly
- FDA approved
- 2023 · Weight management
Dosing requires prescription and clinical supervision. Talk to your healthcare provider about whether Zepbound is right for you.
Quick Answer
Zepbound is FDA-approved for weight loss. People on it lose about 22% of their body weight over 72 weeks. If you weigh 200 pounds, that's 44 pounds. It's the same drug as Mounjaro at a higher dose, approved for weight management instead of diabetes. The doses are tirzepatide 5mg, 10mg, or 15mg weekly. In a 2025 head-to-head trial against Wegovy, Zepbound came out on top by a wide margin. Below: what the trials actually show, how it compares to Wegovy, and the side effects worth knowing.
What is Zepbound?
Zepbound is the brand-name version of tirzepatide made by Eli Lilly for chronic weight management. The FDA approved it in 2023. To qualify, you need a BMI of 30 or higher, or 27 or higher plus a weight-related condition. That includes high blood pressure, type 2 diabetes, sleep apnea, and high cholesterol. Zepbound is the same active ingredient as Mounjaro, just at a higher dose for a different reason. Mounjaro treats diabetes. Zepbound treats obesity. The FDA also approved Zepbound for obstructive sleep apnea in adults with obesity in late 2024.
How it works
Zepbound mimics two of your body's natural fullness signals at once. Scientists call them GLP-1 and GIP. Both get released by your gut when you eat. GLP-1 tells your brain you're full and slows down digestion. GIP adds extra appetite suppression and improves how your body handles sugar. Zepbound is a long-lasting copy of both. It activates both receptors more strongly than your body's own hormones. And it stays in your system for about a week per dose. The two-receptor mechanism is what makes Zepbound stronger than Wegovy on weight loss. Wegovy hits one receptor. Zepbound hits two.
How Zepbound compares
Zepbound vs Mounjaro
Same drug, different dose, different FDA approval. Here's what that actually means for you.
Zepbound and Mounjaro are the same drug. That drug is tirzepatide, made by Eli Lilly. The difference is the dose and what each is FDA-approved for. Mounjaro is approved for type 2 diabetes at 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg weekly. Zepbound is approved for chronic weight management at the same dose ladder. What this means for you. If you don't have diabetes and want to lose weight, Zepbound is the FDA-approved choice. If you have type 2 diabetes and you're trying to manage blood sugar, Mounjaro is the standard. The molecule and dosing are the same. The difference is which insurance code applies and which manufacturer assistance program you qualify for.
Zepbound vs Wegovy
The two FDA-approved chronic-weight-management options. Here's where each wins.
Zepbound and Wegovy are both FDA-approved for chronic weight management. Zepbound produces more weight loss. In a 2025 head-to-head trial, people on Zepbound lost about 20% of their body weight at 72 weeks. People on Wegovy lost about 14%. If you weigh 200 pounds, that's 40 pounds versus 28. Why the gap? Zepbound mimics two of your body's natural fullness signals at once: GLP-1 plus GIP. Wegovy mimics one: GLP-1. The second signal adds extra appetite suppression that GLP-1 alone doesn't. What Wegovy still wins on. The strongest cardiovascular evidence. A 2023 trial enrolled 17,604 adults with obesity and existing heart disease. Wegovy cut their major heart events by 20% over about three years. Zepbound has its own heart trial running, but the data isn't out yet. What this means for you. If maximum weight loss is the goal and you don't have established heart disease, Zepbound is the stronger choice. If you have heart disease and obesity, Wegovy is the option with proven heart benefit today.
Approval status
Zepbound got FDA approval in 2023 for chronic weight management. The SURMOUNT trial program established efficacy across multiple groups. SURMOUNT-1 covered adults with obesity. SURMOUNT-2 covered adults with obesity and type 2 diabetes. SURMOUNT-3 covered weight loss after intensive lifestyle intervention. SURMOUNT-4 covered weight maintenance after initial loss. SURMOUNT-5 was the head-to-head against Wegovy. Zepbound came out on top, 20% body weight loss versus 14% over 72 weeks. SURMOUNT-OSA was the obstructive sleep apnea trial in adults with obesity. The FDA expanded the label in late 2024 to include OSA in this population. The cardiovascular outcomes trial (SURPASS-CVOT) is still running.
Who should not take Zepbound
This page is informational only. Whether Zepbound is appropriate for you depends on your full medical history, current medications, and personal risk factors. Discuss with your healthcare provider for a personalized assessment.
Emerging safety evidence
Bone mineral density emerged as a consideration in a 2026 head-to-head retrospective (Liu et al., J Clin Endocrinol Metab). The study followed 255 GLP-1 RA users against 255 matched controls over 17 months. In people without diabetes, which is Zepbound's main population, the GLP-1 group lost modestly more bone at the total hip. The drop was -1.0% versus -0.6% in controls. In people with diabetes, bone loss was similar between groups. Within the GLP-1 group, bone loss correlated with weight loss. That suggests the effect is weight-loss-mediated rather than a direct drug action. The pattern matches what's seen with bariatric surgery and severe caloric restriction. Fracture-outcome data is still maturing. We don't know yet whether the bone-density signal becomes a fracture problem. Particularly relevant if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia, or prior osteoporosis.
Common questions
Is Zepbound the same as Mounjaro?
Same drug, different brand. Both are tirzepatide made by Eli Lilly. Zepbound is FDA-approved for chronic weight management. Mounjaro is FDA-approved for type 2 diabetes. The molecule and the dose ladder are identical. The labels and insurance codes differ.
How much weight do you lose on Zepbound?
About 22% of your body weight over 72 weeks at the highest dose in SURMOUNT-1. If you weigh 200 pounds, that's roughly 44 pounds. About 91% of people lost at least 5%. About 1 in 3 lost 25% or more. In the head-to-head against Wegovy, the average was about 20%. The slightly lower number reflects the trial design and population. Either way, Zepbound consistently beats Wegovy in head-to-head comparisons.
What are the side effects of Zepbound?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. They tend to be worst at dose escalation and ease over a few weeks. Less common but serious: gallbladder disease, pancreatitis. A 2026 retrospective also showed modest extra bone-density loss in adults without diabetes who lost weight on a GLP-1. Fracture-outcome data isn't there yet. Particularly worth knowing if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia or osteoporosis.
How long does Zepbound take to work?
You'll start losing weight within the first few weeks. But most people don't see meaningful results until they reach the higher doses. The standard ramp-up takes 16-20 weeks: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, then 15mg. The slow ramp lets your body adjust to the gut side effects. Peak weight loss in the trials happened around 60-72 weeks. If you're not losing 5% of body weight by month 6, the FDA label suggests reconsidering treatment.
What other weight-loss drug options exist besides Zepbound?
Wegovy (semaglutide) is a single-receptor GLP-1 with about 15% weight loss. Zepbound beat Wegovy head-to-head in SURMOUNT-5 (20% vs 14%). Saxenda (liraglutide) is a daily injection with about 8% weight loss. Retatrutide is an investigational triple-receptor GLP-1 that reported 28.7% weight loss in Phase 3. Orforglipron is the first oral GLP-1 in Phase 3 with about 11% weight loss.
Can I switch from Mounjaro or Wegovy to Zepbound?
Yes. Many people switch. From Mounjaro, you're already on tirzepatide. Switching to Zepbound usually means staying at the same dose under your prescriber's plan. The transition is mostly a paperwork change. From Wegovy (semaglutide), you're switching molecules. The ramp-up starts at 2.5mg weekly, same as a fresh start on Zepbound. Expect gut side effects to flare during the transition. The weekly cadence stays the same.
Full research profile
The full tirzepatide research profile covers the complete SURMOUNT and SURPASS trial programs, dual GIP/GLP-1 mechanism, head-to-head comparison with semaglutide, sleep apnea outcomes, and the emerging retatrutide triple agonist context.
Zepbound and Mounjaro share the same active ingredient: tirzepatide. The full PSI tirzepatide page covers the SURMOUNT weight-loss trial data, the SURPASS diabetes trial data, the OSA findings, the bone density signal, and how the evidence compares against semaglutide and the next-generation triple agonist retatrutide.
View full Tirzepatide research profile →Comparisons
Related brands
Related research
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.